Vimarsana
Biggest News Aggregation in the World

Page 3 - Poster Number News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Poster Number. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Poster Number Today - Breaking & Trending Today

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress - Vimarsana News

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

DURHAM, N.C., October 12, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that two abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for poster presentations at the upcoming Congress on October 24-27, 2023, in Brussels, Belgium.

Source: yahoo.com
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting -October 11, 2023 at 06:31 am EDT - Vimarsana News

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting -October 11, 2023 at 06:31 am EDT

– Improvement in Serum Neurofilament Light Chain Observed in Both Treatment Arms of Vidofludimus Calcium Over Placebo – – NfL Effect Consistent With Recently Released Data from Separate,...

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting - Vimarsana News

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting 11.10.2023 / 12:30 CET/CEST The issuer is solely responsible for...

Immunic to Participate in Scientific Conferences in October - Vimarsana News

Immunic to Participate in Scientific Conferences in October

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

EQS-News: Immunic to Participate in Scientific Conferences in October - Vimarsana News

EQS-News: Immunic to Participate in Scientific Conferences in October

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific Conferences in October 04.10.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific Conferences in October NEW YORK, October 4, 2023 – I...